Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04747054 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Study acronym: PembroMetaRT
StatusRecruiting
PhasePhase 3
SponsorUNICANCER
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 31, 2026 (before its estimated October 1, 2026 completion). Its status may not reflect the trial's current state.
Trial flagged as At Risk
Primary completion moved at least 12 months later Oct 1, 2025 → Oct 1, 2026
See other at-risk trials from UNICANCER

Record History

  1. Primary completion pushed from Oct 1, 2025 to Oct 1, 2026v9
  2. Enrollment target: 148 to 102 Study sites: 22 to 26 · Eligibility criteria expanded, about 104 words · Secondary endpoints: details revised at 2 of 9 entriesv8 Show 3 more changesShow less
    • Study sites: 22 to 26
    • Eligibility criteria expanded, about 104 words
    • Secondary endpoints: details revised at 2 of 9 entries

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 21 to 22 Eligibility criteria expanded, about 10 wordsv7 Show 1 more changeShow less
    • Eligibility criteria expanded, about 10 words

    See this version in full on ClinicalTrials.gov ↗

  4. Primary endpoint revised Enrollment target: 130 to 148 · Study sites: 20 to 21 · Interventions: Loco-regional radiotherapy (Radiation), Pembrolizumab (Drug) to Chemotherapy (Drug), Loco-regional radiotherapy (Radiation), Pembrolizumab (Drug) · 4 morev6 Show 7 more changesShow less
    • Enrollment target: 130 to 148
    • Study sites: 20 to 21
    • Interventions: Loco-regional radiotherapy (Radiation), Pembrolizumab (Drug) to Chemotherapy (Drug), Loco-regional radiotherapy (Radiation), Pembrolizumab (Drug)
    • Eligibility criteria shortened, about 25 words
    • Secondary endpoints revised (9)
    • Study description expanded, about 4 words
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  5. Primary completion date: Sep 15, 2025 to Oct 1, 2025 Completion date: Sep 15, 2029 to Oct 1, 2029 · Start date changed from estimate of Nov 15, 2021 to Dec 1, 2021v5 Show 2 more changesShow less
    • Completion date: Sep 15, 2029 to Oct 1, 2029
    • Start date changed from estimate of Nov 15, 2021 to Dec 1, 2021
Show 3 earlier versionsHide 3 earlier versions
  1. Start date: Sep 15, 2021 to Nov 15, 2021v4
  2. Trial status: Not Yet Recruiting to Recruiting Start date: Jun 21, 2021 to Sep 15, 2021 · Study sites: 14 to 20 · Primary completion date: Jun 21, 2025 to Sep 15, 2025 · 1 morev3 Show 4 more changesShow less
    • Start date: Jun 21, 2021 to Sep 15, 2021
    • Study sites: 14 to 20
    • Primary completion date: Jun 21, 2025 to Sep 15, 2025
    • Completion date: Jun 21, 2029 to Sep 15, 2029
  3. Start date: Apr 20, 2021 to Jun 21, 2021 Primary completion date: Apr 20, 2025 to Jun 21, 2025 · Completion date: Apr 20, 2029 to Jun 21, 2029v2 Show 2 more changesShow less
    • Primary completion date: Apr 20, 2025 to Jun 21, 2025
    • Completion date: Apr 20, 2029 to Jun 21, 2029
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
UNICANCER
98 trials monitored
See 7 trials at risk
Head & Neck Cancer
2,060 trials monitored
See 120 trials at risk
Study to evaluate the efficacy of treatment by radiotherapy and pembrolizumab in newly diagnosed metastatic head \& neck cancers
Trial Details
NCT Number NCT04747054
Lead Sponsor UNICANCER
Collaborators: GORTEC, National Cancer Institute, France
Conditions Squamous Cell Carcinoma of Head and Neck
Enrollment 102 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov